Fennec Pharmaceuticals Announces Private Offering of Common Shares in Canada

Executive Summary

• Fennec Pharmaceuticals announced a non‑brokered private placement of up to US $5.025 million of common shares at US $7.50 per share, targeted to existing institutional shareholders in Canada (excluding Quebec).
• The offering is expected to close on November 17, 2025, subject to customary closing conditions and regulatory approvals, including TSX consent.
• Proceeds are intended to fund the Company’s ongoing operations and growth initiatives, including further commercialization of its ototoxicity‑prevention products.

Key Details

• Offering Size: Up to US $5,025,000 in gross proceeds.
• Share Price: US $7.50 per common share.
• Shares Offered: Approximately 670,000 shares (US $5,025,000 ÷ $7.50).
• Investor Base: Existing institutional shareholders resident in any Canadian province except Quebec.
• Exemption Used: Listed issuer financing exemption under Part 5A of National Instrument 45‑106 (Prospectus Exemptions).
• Closing Date: Anticipated on November 17, 2025, subject to subscription agreements and customary closing conditions.
• Regulatory Conditions: Requires approval from the Toronto Stock Exchange; shares to be registered in the U.S. under a prospectus supplement if any are issued.
• Hold Period: No hold‑period applicable under Canadian securities law due to exemption.
• Use of Proceeds (implied): General corporate purposes, including support for commercialization of PEDMARK®/PEDMARQSI®, further product development, and working capital.

Notable Quotes

(No direct quotes were provided in the release.)